Acctrue is a leading Chinese software company that provides track and trace solutions. It introduces its track and trace system, which is designed to meet China's CFDA requirements for electronic supervision of drugs. The system allows full supply chain traceability and includes features such as labeling, scanning, aggregation of data, and interfacing with the CFDA system. It provides consultation services and an electronic supervision software system to help customers implement track and trace for imported drugs in accordance with China's regulations.
The document discusses regulations for importing in vitro diagnostic products (IVDs) into India. It explains that IVDs are substances used to diagnose diseases in humans or animals. The Drugs Controller General of India regulates IVD imports to ensure quality, safety and efficacy. IVDs are classified as notified, non-notified, non-critical or semi-critical. Import requirements include application forms, fees, certificates and other documentation depending on the IVD classification. If the application is complete, an import license will be issued within three months. The document provides contact information for Accredited Consultants Private Limited, the organization assisting with IVD imports to India.
To compare GMP requirement of India, US and Europe for tablets.Aakashdeep Raval
The document discusses Good Manufacturing Practice (GMP) requirements for tablet manufacturing in India, the US, and Europe. It provides an in-depth overview of key GMP requirements for tablet production in India, covering general facility requirements, warehousing, production areas, ancillary areas, quality control, personnel, manufacturing operations, equipment, documentation, quality assurance, and validation. The guidelines outline aspects of production and testing that impact quality, including clearly defined and controlled manufacturing processes, change control, training, facilities, equipment, and documentation.
Philadelphia Dropping The Gavel On Counterfeit DrugsChris Miller
The document discusses issues around counterfeit drugs and strategies for addressing them through product serialization and codification. It notes the large and growing problem of counterfeit drugs, outlines regulatory pressures in Europe and the US to implement serialization, and discusses benefits serialization can provide to businesses including improved supply chain management, authentication of products, and protection of brand integrity.
India has a long way to go and needs to quickly align with rest of the world by making changes to its regulations and GMP’s to bring it on par with current requirements not only because of the large EU export based industry but also because even Indians deserve good quality medicines.
This document provides an overview of marketing authorization procedures and premarketing requirements for drug product registration in Southeast Asian countries. It discusses the regulatory framework in the ASEAN region and details the marketing authorization processes in major Southeast Asian countries like Singapore, Malaysia, Thailand, Indonesia, and the Philippines. The key steps involved are application submission, evaluation, and the regulatory decision. Requirements like dossier format, samples, certificates, and administrative documents are also summarized. Finally, some regulatory challenges around GMP compliance, labeling requirements, authorization timelines, and country-specific rules are highlighted.
The document discusses India's drug regulatory system. The Drug Controller General of India regulates drugs and medical devices in the country to ensure quality, safety and efficacy. New drugs require approval through a New Drug Application process which involves submitting documentation on manufacturing, non-clinical studies, and clinical trials for review. It takes about a year to review an NDA and various forms and fees are involved in the approval and import license application processes.
Pharma Uptoday Monthly Magazine Volume 14 Issue May 2015Sathish Vemula
This issue of Pharma Uptoday magazine covers the following topics:
1. New regulations for ozone systems used to disinfect pharmaceutical water under the Biocidal Products Regulation. Major manufacturers are working to get ozone approved as an active ingredient and register generation systems.
2. An overview of API manufacturing sites for the European market based on data in the EudraGMDP database, which shows the majority are located in India, China, and within the EEA. However, the data is not fully complete.
3. Plans by the FDA to change their facility inspection approach to provide both compliance assessments and recognize excellence in quality management systems. This could impact inspection frequency and post-approval flexibility.
The document discusses regulations for importing in vitro diagnostic products (IVDs) into India. It explains that IVDs are substances used to diagnose diseases in humans or animals. The Drugs Controller General of India regulates IVD imports to ensure quality, safety and efficacy. IVDs are classified as notified, non-notified, non-critical or semi-critical. Import requirements include application forms, fees, certificates and other documentation depending on the IVD classification. If the application is complete, an import license will be issued within three months. The document provides contact information for Accredited Consultants Private Limited, the organization assisting with IVD imports to India.
To compare GMP requirement of India, US and Europe for tablets.Aakashdeep Raval
The document discusses Good Manufacturing Practice (GMP) requirements for tablet manufacturing in India, the US, and Europe. It provides an in-depth overview of key GMP requirements for tablet production in India, covering general facility requirements, warehousing, production areas, ancillary areas, quality control, personnel, manufacturing operations, equipment, documentation, quality assurance, and validation. The guidelines outline aspects of production and testing that impact quality, including clearly defined and controlled manufacturing processes, change control, training, facilities, equipment, and documentation.
Philadelphia Dropping The Gavel On Counterfeit DrugsChris Miller
The document discusses issues around counterfeit drugs and strategies for addressing them through product serialization and codification. It notes the large and growing problem of counterfeit drugs, outlines regulatory pressures in Europe and the US to implement serialization, and discusses benefits serialization can provide to businesses including improved supply chain management, authentication of products, and protection of brand integrity.
India has a long way to go and needs to quickly align with rest of the world by making changes to its regulations and GMP’s to bring it on par with current requirements not only because of the large EU export based industry but also because even Indians deserve good quality medicines.
This document provides an overview of marketing authorization procedures and premarketing requirements for drug product registration in Southeast Asian countries. It discusses the regulatory framework in the ASEAN region and details the marketing authorization processes in major Southeast Asian countries like Singapore, Malaysia, Thailand, Indonesia, and the Philippines. The key steps involved are application submission, evaluation, and the regulatory decision. Requirements like dossier format, samples, certificates, and administrative documents are also summarized. Finally, some regulatory challenges around GMP compliance, labeling requirements, authorization timelines, and country-specific rules are highlighted.
The document discusses India's drug regulatory system. The Drug Controller General of India regulates drugs and medical devices in the country to ensure quality, safety and efficacy. New drugs require approval through a New Drug Application process which involves submitting documentation on manufacturing, non-clinical studies, and clinical trials for review. It takes about a year to review an NDA and various forms and fees are involved in the approval and import license application processes.
Pharma Uptoday Monthly Magazine Volume 14 Issue May 2015Sathish Vemula
This issue of Pharma Uptoday magazine covers the following topics:
1. New regulations for ozone systems used to disinfect pharmaceutical water under the Biocidal Products Regulation. Major manufacturers are working to get ozone approved as an active ingredient and register generation systems.
2. An overview of API manufacturing sites for the European market based on data in the EudraGMDP database, which shows the majority are located in India, China, and within the EEA. However, the data is not fully complete.
3. Plans by the FDA to change their facility inspection approach to provide both compliance assessments and recognize excellence in quality management systems. This could impact inspection frequency and post-approval flexibility.
Clinical Trial Costs in Emerging Geographies - Stephen PorterTTC, llc
1. VDDI Pharmaceuticals utilizes a virtual business model to outsource drug development functions like preclinical and clinical trials to reduce costs.
2. Xemilofiban is a drug product that has already undergone Phase II and III trials and has proven safety and efficacy advantages over existing products.
3. Conducting multi-center Phase II and III trials in China provides an opportunity to secure Chinese regulatory approval and save 2-4 years bringing the drug to market in China compared to other regions.
The document discusses Oracle's Pedigree and Serialization Manager (OPSM) solution for maintaining integrity in pharmaceutical supply chains. It outlines challenges like counterfeiting and the need for serialization, ePedigree, and track-and-trace capabilities. OPSM provides a single application to manage serialization and pedigree data across global supply chains in compliance with evolving regulations. It leverages Oracle Fusion Middleware and databases to handle large data volumes securely and with high performance.
Copp - CERTIFICATE OF PHARMACEUTICAL PRODUCTSuraj Pamadi
The document discusses the Certificate of Pharmaceutical Product (CoPP), which is issued by regulatory authorities to help importing countries assess the quality of pharmaceutical products. It outlines the importance of the CoPP for product registration in other countries. The summary also describes the application process for obtaining a CoPP in India, including requirements for documentation, inspections, and the format of the certificate.
This document summarizes regulations and guidelines for conducting pharmaceutical clinical trials in India. It outlines the major regulatory bodies like DCGI, DGFT, and GEAC. It describes the statutory functions of central and state governments regarding drug licensing, approvals, and quality monitoring. Responsibilities of sponsors, investigators, and ethics committees are provided. Key aspects like clinical trial categories, amendments, safety reporting, and biologics/device regulations are summarized.
Indian regulatory requirements - industrial pharmacy 2Jafarali Masi
Indian Regulatory Requirements: Central Drug Standard Control Organization (CDSCO) and State Licensing Authority: Organization, Responsibilities, Certificate of Pharmaceutical Product (COPP), Regulatory requirements and approval procedures for New Drugs
New Drug approval process in India, rules, and regulation according to schedule Y (Drug and cosmetics act 1940 ).
Fees and form for the submission of application.
Regulatory Framework: SOPs For Ethical Regulation Of Drugsbiinoida
The document outlines standard operating procedures and regulatory requirements for clinical trials in India. It discusses maintaining proper documentation for regulatory compliance, including investigator files, informed consent forms, and safety reporting. The order of documents in investigator files is provided. It also summarizes the role and functions of the Central Drugs Standard Control Organisation as the approving authority for drugs, medical devices, and clinical trials in India.
The Central Drugs Standard Control Organization (CDSCO) is India's main drug regulatory body. It oversees the approval process for pharmaceuticals, medical devices, and clinical trials. The approval process involves submitting application forms along with documents covering chemistry/manufacturing, pre-clinical and clinical trial data to CDSCO. Applications are reviewed and may receive approval, approvable, or non-approvable letters in around one year. Bioequivalence studies require separate approval and involve submitting protocols, ethics committee approval and other documents through the online SUGAM portal.
Market Exclusivity Under the Waxman-Hatch ActMichael Swit
March 19, 2007 presentation to the San Diego County Bar Association IP Section, with a focus on:
•Orphan Drug Exclusivity (Seven Years)
•Five-Year Exclusivity
•Three-Year Exclusivity
•Pediatric Exclusivity (Six Months)
•180-Day Exclusivity
"Description:
Red biotechnology (RB) refers to the biotechnology applied in pharmaceutical production and it has become the most important part in biotechnology industry. About 60% of achievements in biotechnology in the world are applied in production of bio-pharmaceuticals. At present, RB products mainly include gene recombinant drugs, blood products, vaccines, diagnostic reagents, etc. What is the current production situation of different RB products in China?
Driven by its substantial environmental or economic benefits, China’s RB industry has witnessed fast development and has played an increasingly important role in Chinese economic growth. However, the overall development of China’s RB industry remains in growth stage, and still has an enormous gap compared with developed countries. What is the future trend of Chinese RB industry development? What are the relevant supporting policies on Chinese RB industry? What have been the popular cutting-edge technologies in China in recent years? Where are the investment opportunities and what is the investment mode in China?
What is covered in this report?
- Overview of China’s red biotechnology;
- Detailed analysis of each sub-categories of red biotechnologies in China: gene recombinant drugs, blood products, vaccines, diagnostic reagent, etc., in terms of market data, major players, technical suppliers, technologies or R&D situations;
- Future prospects of each category of red biotechnologies, with key influencing factors and commercial opportunities
- Profiles of major players and research institutes
- Related policies and regulations
What benefits will you get?
- Gain a clear understanding about the industry landscape and latest developments in R&D, production, technology advancement and future trends in China’s red biotechnology;
- Keep informed of the precise development situation of key RB products with basic data and latest info;
- Gain reasonable and constructive suggestions on market opportunities in China’s RB fields;
- Figure out, current trend and future growth prospect of red biotechnology in China;
- Know more about how innovative players and research groups are carrying out innovation, collaboration and achieving commercial success in China.
"
The Central Drug Standard Control Organisation (CDSCO) is India's main drug regulatory body. It regulates pharmaceuticals, medical devices, and clinical trials. CDSCO functions under the Ministry of Health and Family Welfare. It oversees drug approval processes, clinical trial approval, import/export of drugs, medical devices regulation, and operates an online licensing portal called SUGAM. CDSCO's head office is in New Delhi and it has various zonal, sub-zonal, and port offices that perform regulatory functions like GMP audits and sample testing.
What is COPPs? How to apply for COPPs (Certificate of Pharmaceutical Products)?Ajay kamboj
The document discusses Certificate of Pharmaceutical Products (COPP), which is a certificate issued by the World Health Organization (WHO) that is required for pharmaceutical companies to export medicines globally. It regulates the import and export of drugs in India. To apply for a COPP, manufacturers must submit documents such as their manufacturing license, product lists, standard operating procedures, equipment lists, staff details and more to the relevant authorities. A COPP is valid for 3 years and helps ensure drugs meet quality standards before leaving the country.
The Central Drugs Standard Control Organization (CDSCO) is the main regulatory body for pharmaceuticals, medical devices, and clinical trials in India. CDSCO approves new drugs, regulates import/export and manufacturing of drugs, medical devices, and cosmetics. It has various zonal and regional offices. The document outlines CDSCO's role in drug approval process, clinical trials, regulation of cosmetics, and the new Medical Device Rules of 2016.
A brief introductory presentation about National Drug Regulatory Authority of India for Indian Pharmaceuticals and Medical Devices i.e. CDSCO. By Pratibha Chaudhary, pursuing Mpharm DRA from Amity University.
Dyadic is developing a new biological platform using the C1 gene expression system for vaccine and drug development and production. The C1 system uses the fungus C1 to produce enzymes and biologics at high levels. Dyadic has successfully used C1 to express various therapeutic proteins, antibodies, antigens, and virus-like particles. They are also working on improving the C1 system through protease deletion strains and glycoengineering to produce proteins with more human-like glycans. Dyadic believes the C1 system offers advantages over traditional systems for cost-effective and scalable production of biologics.
Case study with reference to drug regulatory affairsRakesh Wani
This document provides information on drug regulation in India. It discusses the following:
1. Drug regulation is governed by both central and state governments under the Drugs and Cosmetics Act of 1940. The key central regulatory body is the Central Drugs Standard Control Organization (CDSCO).
2. CDSCO oversees functions like new drug approval, clinical trials approval, import/export regulation, and banning of drugs. It has various zonal and sub-zonal offices across India.
3. Schedules M and Y of the Drugs and Cosmetics Rules provide guidance on good manufacturing practices for facilities and guidelines for approval of new drugs and conducting clinical trials. Strict adherence to these is required for
How to apply for COPPs (Certificate of Pharmaceutical Products)?ambitbiomedix12
The certificate of a pharmaceutical products (COPPs) is a certificate issued in the format recommended by the World Health Organization (WHO), which establishes the status of the pharmaceutical product and of the applicant for this certificate in the exporting country. Read More: https://bit.ly/31cfTYl
Raaj Global Pharma Regulatory Affairs Consultants Thane-mumbai profile-updat...Rajashri Survase Ojha
Raaj-GPRAC is a Thane-Mumbai (India) based agency.
Our offerings includes but not limited to making Regulatory filing strategy, Preparation of pharmaceutical product registration dossier, filing assistance, response to regulatory queries, life cycle management, regulatory compliance audit and Training.
We offer flexible and need based services to meet customer/client requirements so as to save time and cost.
WHODrug Koda, developed by Uppsala Monitoring Centre (UMC), is an automated coding service, which uses artificial intelligence (AI) to automate the coding of drug names and ATC selections, improving consistency and operational efficiency. It can also be used to accelerate dictionary upgrades, including the transition from WHODrug B2 format to B3.
Through API (Application Programming Interface) web services, the coding engine can be integrated with custom or off-the-shelf drug safety, medical coding, or data management systems.
In this webinar, Perficient and UMC discussed WHODrug Koda and how you can integrate it into your medical coding activities.
As you start to map out your global strategy beyond the US, Canada and Europe, there are six key steps to follow and multiple regulations to consider. Harmonization has increased in recent years, yet most countries still maintain distinct medical device regulatory systems. Careful analysis on a market-by-market basis will help you to fully realize compliance requirements affecting a particular market. Explore these six steps as we reveal insights into the unique medical device regulations affecting markets in Russia, Brazil, Japan, China, and India.
Clinical Trial Costs in Emerging Geographies - Stephen PorterTTC, llc
1. VDDI Pharmaceuticals utilizes a virtual business model to outsource drug development functions like preclinical and clinical trials to reduce costs.
2. Xemilofiban is a drug product that has already undergone Phase II and III trials and has proven safety and efficacy advantages over existing products.
3. Conducting multi-center Phase II and III trials in China provides an opportunity to secure Chinese regulatory approval and save 2-4 years bringing the drug to market in China compared to other regions.
The document discusses Oracle's Pedigree and Serialization Manager (OPSM) solution for maintaining integrity in pharmaceutical supply chains. It outlines challenges like counterfeiting and the need for serialization, ePedigree, and track-and-trace capabilities. OPSM provides a single application to manage serialization and pedigree data across global supply chains in compliance with evolving regulations. It leverages Oracle Fusion Middleware and databases to handle large data volumes securely and with high performance.
Copp - CERTIFICATE OF PHARMACEUTICAL PRODUCTSuraj Pamadi
The document discusses the Certificate of Pharmaceutical Product (CoPP), which is issued by regulatory authorities to help importing countries assess the quality of pharmaceutical products. It outlines the importance of the CoPP for product registration in other countries. The summary also describes the application process for obtaining a CoPP in India, including requirements for documentation, inspections, and the format of the certificate.
This document summarizes regulations and guidelines for conducting pharmaceutical clinical trials in India. It outlines the major regulatory bodies like DCGI, DGFT, and GEAC. It describes the statutory functions of central and state governments regarding drug licensing, approvals, and quality monitoring. Responsibilities of sponsors, investigators, and ethics committees are provided. Key aspects like clinical trial categories, amendments, safety reporting, and biologics/device regulations are summarized.
Indian regulatory requirements - industrial pharmacy 2Jafarali Masi
Indian Regulatory Requirements: Central Drug Standard Control Organization (CDSCO) and State Licensing Authority: Organization, Responsibilities, Certificate of Pharmaceutical Product (COPP), Regulatory requirements and approval procedures for New Drugs
New Drug approval process in India, rules, and regulation according to schedule Y (Drug and cosmetics act 1940 ).
Fees and form for the submission of application.
Regulatory Framework: SOPs For Ethical Regulation Of Drugsbiinoida
The document outlines standard operating procedures and regulatory requirements for clinical trials in India. It discusses maintaining proper documentation for regulatory compliance, including investigator files, informed consent forms, and safety reporting. The order of documents in investigator files is provided. It also summarizes the role and functions of the Central Drugs Standard Control Organisation as the approving authority for drugs, medical devices, and clinical trials in India.
The Central Drugs Standard Control Organization (CDSCO) is India's main drug regulatory body. It oversees the approval process for pharmaceuticals, medical devices, and clinical trials. The approval process involves submitting application forms along with documents covering chemistry/manufacturing, pre-clinical and clinical trial data to CDSCO. Applications are reviewed and may receive approval, approvable, or non-approvable letters in around one year. Bioequivalence studies require separate approval and involve submitting protocols, ethics committee approval and other documents through the online SUGAM portal.
Market Exclusivity Under the Waxman-Hatch ActMichael Swit
March 19, 2007 presentation to the San Diego County Bar Association IP Section, with a focus on:
•Orphan Drug Exclusivity (Seven Years)
•Five-Year Exclusivity
•Three-Year Exclusivity
•Pediatric Exclusivity (Six Months)
•180-Day Exclusivity
"Description:
Red biotechnology (RB) refers to the biotechnology applied in pharmaceutical production and it has become the most important part in biotechnology industry. About 60% of achievements in biotechnology in the world are applied in production of bio-pharmaceuticals. At present, RB products mainly include gene recombinant drugs, blood products, vaccines, diagnostic reagents, etc. What is the current production situation of different RB products in China?
Driven by its substantial environmental or economic benefits, China’s RB industry has witnessed fast development and has played an increasingly important role in Chinese economic growth. However, the overall development of China’s RB industry remains in growth stage, and still has an enormous gap compared with developed countries. What is the future trend of Chinese RB industry development? What are the relevant supporting policies on Chinese RB industry? What have been the popular cutting-edge technologies in China in recent years? Where are the investment opportunities and what is the investment mode in China?
What is covered in this report?
- Overview of China’s red biotechnology;
- Detailed analysis of each sub-categories of red biotechnologies in China: gene recombinant drugs, blood products, vaccines, diagnostic reagent, etc., in terms of market data, major players, technical suppliers, technologies or R&D situations;
- Future prospects of each category of red biotechnologies, with key influencing factors and commercial opportunities
- Profiles of major players and research institutes
- Related policies and regulations
What benefits will you get?
- Gain a clear understanding about the industry landscape and latest developments in R&D, production, technology advancement and future trends in China’s red biotechnology;
- Keep informed of the precise development situation of key RB products with basic data and latest info;
- Gain reasonable and constructive suggestions on market opportunities in China’s RB fields;
- Figure out, current trend and future growth prospect of red biotechnology in China;
- Know more about how innovative players and research groups are carrying out innovation, collaboration and achieving commercial success in China.
"
The Central Drug Standard Control Organisation (CDSCO) is India's main drug regulatory body. It regulates pharmaceuticals, medical devices, and clinical trials. CDSCO functions under the Ministry of Health and Family Welfare. It oversees drug approval processes, clinical trial approval, import/export of drugs, medical devices regulation, and operates an online licensing portal called SUGAM. CDSCO's head office is in New Delhi and it has various zonal, sub-zonal, and port offices that perform regulatory functions like GMP audits and sample testing.
What is COPPs? How to apply for COPPs (Certificate of Pharmaceutical Products)?Ajay kamboj
The document discusses Certificate of Pharmaceutical Products (COPP), which is a certificate issued by the World Health Organization (WHO) that is required for pharmaceutical companies to export medicines globally. It regulates the import and export of drugs in India. To apply for a COPP, manufacturers must submit documents such as their manufacturing license, product lists, standard operating procedures, equipment lists, staff details and more to the relevant authorities. A COPP is valid for 3 years and helps ensure drugs meet quality standards before leaving the country.
The Central Drugs Standard Control Organization (CDSCO) is the main regulatory body for pharmaceuticals, medical devices, and clinical trials in India. CDSCO approves new drugs, regulates import/export and manufacturing of drugs, medical devices, and cosmetics. It has various zonal and regional offices. The document outlines CDSCO's role in drug approval process, clinical trials, regulation of cosmetics, and the new Medical Device Rules of 2016.
A brief introductory presentation about National Drug Regulatory Authority of India for Indian Pharmaceuticals and Medical Devices i.e. CDSCO. By Pratibha Chaudhary, pursuing Mpharm DRA from Amity University.
Dyadic is developing a new biological platform using the C1 gene expression system for vaccine and drug development and production. The C1 system uses the fungus C1 to produce enzymes and biologics at high levels. Dyadic has successfully used C1 to express various therapeutic proteins, antibodies, antigens, and virus-like particles. They are also working on improving the C1 system through protease deletion strains and glycoengineering to produce proteins with more human-like glycans. Dyadic believes the C1 system offers advantages over traditional systems for cost-effective and scalable production of biologics.
Case study with reference to drug regulatory affairsRakesh Wani
This document provides information on drug regulation in India. It discusses the following:
1. Drug regulation is governed by both central and state governments under the Drugs and Cosmetics Act of 1940. The key central regulatory body is the Central Drugs Standard Control Organization (CDSCO).
2. CDSCO oversees functions like new drug approval, clinical trials approval, import/export regulation, and banning of drugs. It has various zonal and sub-zonal offices across India.
3. Schedules M and Y of the Drugs and Cosmetics Rules provide guidance on good manufacturing practices for facilities and guidelines for approval of new drugs and conducting clinical trials. Strict adherence to these is required for
How to apply for COPPs (Certificate of Pharmaceutical Products)?ambitbiomedix12
The certificate of a pharmaceutical products (COPPs) is a certificate issued in the format recommended by the World Health Organization (WHO), which establishes the status of the pharmaceutical product and of the applicant for this certificate in the exporting country. Read More: https://bit.ly/31cfTYl
Raaj Global Pharma Regulatory Affairs Consultants Thane-mumbai profile-updat...Rajashri Survase Ojha
Raaj-GPRAC is a Thane-Mumbai (India) based agency.
Our offerings includes but not limited to making Regulatory filing strategy, Preparation of pharmaceutical product registration dossier, filing assistance, response to regulatory queries, life cycle management, regulatory compliance audit and Training.
We offer flexible and need based services to meet customer/client requirements so as to save time and cost.
WHODrug Koda, developed by Uppsala Monitoring Centre (UMC), is an automated coding service, which uses artificial intelligence (AI) to automate the coding of drug names and ATC selections, improving consistency and operational efficiency. It can also be used to accelerate dictionary upgrades, including the transition from WHODrug B2 format to B3.
Through API (Application Programming Interface) web services, the coding engine can be integrated with custom or off-the-shelf drug safety, medical coding, or data management systems.
In this webinar, Perficient and UMC discussed WHODrug Koda and how you can integrate it into your medical coding activities.
As you start to map out your global strategy beyond the US, Canada and Europe, there are six key steps to follow and multiple regulations to consider. Harmonization has increased in recent years, yet most countries still maintain distinct medical device regulatory systems. Careful analysis on a market-by-market basis will help you to fully realize compliance requirements affecting a particular market. Explore these six steps as we reveal insights into the unique medical device regulations affecting markets in Russia, Brazil, Japan, China, and India.
Bilcare provides one-stop track and trace and authentication solutions for securing supply chains. It has developed a unique ncID technology that embeds a tamper-evident fingerprint in products to enable authentication as they move through supply chains. Bilcare offers a comprehensive solution that combines track and trace with authentication using ncID tags with a unique magnetic pattern to identify products and ensure supply chain integrity. Their solution establishes supply chain intelligence and provides end-to-end visibility across international supply chains.
IFPMA-TFDA Workshop on Couterfeit Medicines
‘Integrated Approach Against Fake Medicines’
Session 2: Supply Chain Integrity
On 6th February 2015
At Taipei International Convention Center
Taipei, Taiwan
Anti-Counterfeiting Use Case | Topic #4 of PharmaLedger's 1st Open Webinar PharmaLedger
Learn more about Anti-Counterfeiting through PharmaLedger’s Use Case presentation during our #1 Open Webinar about a Trust-Centric Healthcare Journey.
In this Anti-Counterfeiting Use Case presentation, you will find:
An introduction to the Anti-Counterfeiting use case presented by Daniel Fritz (Novartis) and Alberto López (Imprensa Nacional Casa da Moeda)
The current problem of counterfeiting
Anti-counterfeiting information flow
PharmaLedger Anti-Counterfeit Use Case vision
Anti-counterfeiting example – banknotes
Authentication feature example: Uniqode® physical and digital security
Anti-counterfeiting data collaboration
Anti-counterfeiting use case value proposition
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
NEARCHAIN - Leveraging NFC and Blockchain in Pharmaceutical Supply chain to p...IRJET Journal
This document proposes a solution called NEARCHAIN that leverages NFC and blockchain technologies to track pharmaceutical drugs through the supply chain and prevent counterfeiting. It describes how counterfeit drugs are a major problem, affecting up to 25% of medicines in poor countries. The complex pharmaceutical supply chain makes it difficult to track counterfeits. The proposed solution uses NFC tags on drug packages and publishes the tag information and details to the blockchain at each supply chain stage using smart contracts. This provides transparency and prevents counterfeiting by allowing verification of authentic drugs at any point. The solution aims to improve reliability, scalability and efficiency in the pharmaceutical supply chain.
This document discusses a technology incubation lab at a global biopharmaceutical company. The lab aims to accelerate innovation, support learning across departments, and bring in emerging technologies. It focuses on using technology to improve productivity in research and development, commercial operations, and manufacturing. Specific projects highlighted include using AI for clinical trial recruitment and digitizing manufacturing standard operating procedures.
The document summarizes the Indian medical device market. It finds that the market was worth $5.1 billion in 2012 and is expected to reach $9.2 billion by 2016, growing at a 15.8% CAGR. Currently, 72% of medical devices sold in India are imported, with imports favored due to taxation policies. The market is dominated by multinational companies in high-tech segments, while domestic players cater to lower-tech areas. The top opportunities are in medical and diagnostic equipment, expected to reach $6 billion and grow over 17% by 2017. Key drivers of growth are increasing incomes, insurance coverage, and government support of healthcare. Barriers include low penetration, over-reliance on
A Trust-Centric Healthcare Journey | Full Presentation of PharmaLedger's 1st ...PharmaLedger
In this #1 Open Webinar | A trust-centric healthcare journey presentation, you will find:
An introduction to the PharmaLedger project presented by Lynn Wang (Johnson & Johnson)
Topic 1 | Clinical Supply Traceability presented by Francesco Spoto (Novartis) and Chad Sklodosky (Pfizer)
Topic 2 | Finished Goods Traceability presented by Dr Jan Wortmann (Bayer) and Bernhard Salb (Roche)
Topic 3 | ePI – Electronic Product Information presented by Patrick Maher (Novartis) and Ken Thursby (MSD)
Topic 4 | Anti-Counterfeiting presented by Daniel Fritz (Novartis) and Alberto Lòpez (Imprensa Nacional Casa da Moeda)
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
Glucose Strip, Urine Strip and Pregnancy Strip are three categories of IVD Strips that required to manufacturing in good quality and cost effective manner with accurate release timing and effective marketing strategy. To manufacture these strips, it should be well equipped with infrastructure, experienced team of research experts, proper regulatory compliances, dedicated lab facility and well developed supply chain network.
𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐮𝐬
NIIR PROJECT CONSULTANCY SERVICES, DELHI
An ISO 9001:2015 Company
ENTREPRENEUR INDIA
106-E, Kamla Nagar, Opp. Mall ST,
New Delhi-110007, India.
Email: npcs.ei@gmail.com
info@entrepreneurindia.co
Tel: +91-11-23843955, 23845654, 23845886
Mobile: +91-9097075054, 8800733955
Website: https://www.entrepreneurindia.co
https://www.niir.org
Chinese Microfluidics Industry 2018 Report by Yole DeveloppementYole Developpement
Will the Chinese microfluidics industry change the worldwide microfluidic landscape?
More information on that report at: https://www.i-micronews.com/category-listing/product/chinese-microfluidics-industry-2018.html
Implementing Agile in an FDA Regulated EnvironmentTechWell
Developing medical devices that are subject to FDA approval has traditionally followed the waterfall methodology, largely due to the structure of the regulations that govern development practices. But we know from myriad case studies in different industries that agile methodologies are far superior in providing the highest value to customers in the shortest time to market. Neal Herman shares how one developer of complex medical devices embraced agile software development practices and proved that it could not only develop software faster with higher quality but also meet all regulatory requirements. Convincing the internal quality management, systems engineering, and regulatory departments was difficult, but the software department was able to overcome these obstacles and fundamentally change the company’s philosophy on product development. Since 2012, software development productivity is up 100 percent, and quality is up 200 percent. Now, after seeing these gains from the software department, agile is being rolled out to all areas of R&D including hardware.
REGISTRATION OF INDIAN DRUG PRODUCT IN OVERSEAS MARKET.pptxMurthujavali Miper
The regulatory affairs (RA) department of a pharmaceutical company is responsible for obtaining approval for new pharmaceutical products and ensuring that approval is maintained for as long as the company wants to keep the product on the market.
What are leadership The simple definizion is that leadership - islorileemcclatchie
What are leadership? The simple definizion is that leadership - is the art of motivating a group of people to act toward achieving a common goal. In a business setting it can mean directing workers and colleagues with a strategy to meet the company's needs.
This leadership definition captures the essentials of being able and prepared to inspire others. Effective leadership is based upon ideas (whether original or borrowed), but won't happen unless those ideas can be communicated to others in a way that engages them enough to act as the leader wants them to act.
Put even more simply, the leader is the inspiration for and director of the action. They are a person in the group that possesses the combination of personality and leadership skills to make others want to follow their direction.
<To develop a new medical device for China market >
< PMGT 699 – Applied Project Management >
Prepared By
< Soumitra G Shilotri >
<02/11/2020>
1.Executive Summary 3
2.Project Overview 5
2.1 Project Description 5
2.2 Problem Statement 5
2.3 Goals 5
2.4 Project Background 7
2.5 Product Objectives 7
2.6 Assumptions, Constraints and Dependencies 7
2.7 Project Deliverables 8
2.8 Schedule and Budget Summary 9
2.9 Evolution of the Plan 10
2.10 Definitions and Acronyms 10
3.Stakeholder Register 12
4.Schedule Component 14
5.Resource Plan with RACI 18
5.1Overview/Purpose 18
5.2 Resourcing Strategy & Assumption 18
5.3 Resourcing Development 18
6.Risk Management Plan 21
6.1 Review of Risk Management Plan 21
6.2 Risk Identification 21
7.Communications Plan 24
8. Procurement 28
9. Cost…………………………………………………………………………………………..30
10. Integrated Change Control 341.Executive Summary
1.1 Introduction
Johnson and Johnson (J&J) is an American multinational company that develops medical devices, pharmaceutical drugs and consumer products. J&J is one of the largest medical device companies in the world. There are various subsidiaries of J&J, however the medical device business of J&J includes 3 global franchises; mainly Ethicon (surgical), Bio-sense Webster (Cardiovascular & Speciality solutions) and Depuy Synthes (Orthopaedics). J&J has a presence in over 100 countries worldwide and the medical device companies manufactures and does R&D on various different kinds of surgical devices, implants that are used by doctors in laparoscopic surgeries.
Current project that I will be working on is named as Project RoadRunner by the project team. The project is to develop a new medical device implant for China market. The implant is a sterile product that is used by surgeons during bariatric surgeries. This implant is used alongside a vascular stapler and will improve the staple line integrity, force to fire and staple performance during surgery. This will be a big boost in the existing line of stapling implants by improving performance reliability and decrease market complaints. So far for earlier legacy devices, we were using 2-D st ...
Positive id PositiveID Corporation (OTCBB:PSID) Conference PresentationInvestorideas.com
PositiveID Corporation (OTCBB:PSID) develops unique medical devices and molecular diagnostic systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MFS, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays.
QualiMedd is an independent UK-based consultancy established in 1990 that specializes in providing quality and regulatory services to medical device and in vitro diagnostic companies. They offer assistance with ISO certification, implementing quality systems, technical files, design dossiers, FDA and EU requirements. Their managing director Jim Mackenzie has over 35 years of experience in the medical industry. QualiMedd works with companies of all sizes to help ensure they meet international standards and directives.
ePI – Electronic Product Information Use Case | Topic #3 of PharmaLedger's 1s...PharmaLedger
Learn more about ePI | Electronic Product Information through PharmaLedger’s Use Case presentation during our #1 Open Webinar about a Trust-Centric Healthcare Journey.
In this ePI | Electronic Product Information Use Case presentation, you will find:
An introduction to the ePi use case presented by Patrick Maher (Novartis) and Ken Thursby (MSD)
Current paper product information leaflets and the disadvantages
Advantages of digitising product information leaflets using blockchain
Current product information (leaflet) lifecycle
EMA/HMA key principles
PharmaLedger future vision with blockchain
Connecting the supply chain through the 2D data matrix
PharmaLedger project roadmap
Stakeholder and value proposition
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.
The document provides an overview of current solutions in the pharmaceutical sector for tracking products throughout the supply chain. It discusses five main components of projects: project management, coding, vision, mechanical handling, and data management. Current solutions discussed include mass serialization at the line of packaging, activation and data capture of unique identifiers, use of middleware to synchronize data, and external authentication systems to verify products. Security layers including overt, covert and forensic marking techniques are also overviewed. The presentation concludes with examples of federated authentication systems and serialization standards used in track and trace solutions.
Access 2-healthcare company introduction deck - english - may 2018Access-2-Healthcare
Market Entry for Medical Technology / Medical Device companies, in Asia Pacific, Europe, US
#Commercialisation
#Healthcare
#Regulatory
#Quality
#SoftwareValidation / #Verification
#DueDiligence
#LicenseHolding
#Go-to-MarketStrategy
#MarketStudies
Similar to v2 Serialization solution by Acctrue (20)
Access 2-healthcare company introduction deck - english - may 2018
v2 Serialization solution by Acctrue
1. 360° 供应链管理专家
January 1, 2009 Date
中 国 物 联 网 行 业 先 锋
The general solution of
EDMC of CFDA on
imported drugs
Acctrue Technology
Leo Zhang(Sales Manager)
Liuwenxi (Technical Director)
1
2. 中国物联网行业先锋
1. Acctrue Brief
2. T&T Requirements from CFDA
3. Acctrue T&T System Design
5. Delivery And Service
4. Acctrue T&T System Introduction
Contents
3. 3
中国物联网行业先锋About us
Founded on 1998 at Beijing, Acctrue is one of the national
key software enterprise with double software certification
in Beijing.
We have more than 400 employees who distributed at 8
regions throughout China.
We are the first enterprise that implemented
pharmaceutical electronic supervision code e-coding
system in China.
Our Track & Trace solution has been widely used in more
than 15000 production lines accross15 different industries.
4. 4
中国物联网行业先锋
4
Acctrue is high-tech enterprise of National Torch Plan,
supported by technology support funds of National
Development and Reform Commission, Ministry of
Industry and Information Technology
Acctrue provides the solution consultation, self-owned
software as well as hardware integration.
With more than 12 software patent and 77 software
copyright, Acctrue has been recognized as the leading
supplier in the field of industry software.
From 2005,Acctrue had implemented projects for more
than 2000 pharmaceutical clients, domestically and
globally. 18 of Top 25 global pharmaceutical companies
adopted our solutions.
5. 中国物联网行业先锋Full Supply Chain Traceability Solution
5
ERP/OA
procure inventory production quality finance sales
Production
quality mgt
Market
mgt
Anti-fake,
transshipment
sales
Material
warehouse
mgt
Raw
material
mgt
Plan, material
inputting mgt
Labeling and
scanning
Finished item
warehouse
mgt
Distribution
direction
mgt
Raw material
procure
Material inputting
in production
Packaging
barcoding
System Interface
Raw material
inventory
Product
inventory
Distribution
mgt
Tracking
Consumer
mgt
Post sales
service mgt
Tracing
Quality
mgt
Note:
Mgt=management
6. 中国物联网行业先锋
QA/REWORK
Station
Warthouse Station
Manufacturing sites – Process and integration levels
Running Batch Modify Batch Shipment Modify Shipment
Level4Level3Level2Level1
Enterprise
Application
Site
Application
(For each site)
Line Controller
(For each line and
Reworking station)
Device Level
7. 7
Pioneer of Chinese Internet of ThingsAcctrue Service
7
Consulting
Service
Production Line
/Equipment
Manufacturing
IT Outsourcing
Service
Software
Development/
Authentification
Service
T&T SW&
HW On-site
Delivery
Supply
Chain
8. 中国物联网行业先锋
8
Headquarter in Beijing
8 branches in China
1 branch in USA
Acctrue in China
Central Region
North Region
South Region
East Region
NEast Region
NWest Region
WSouth Region
Shan Dong Region
9. 中国物联网行业先锋
9
Awards and Recognition
Beijing High-tech Enterprise Certification
China Food Cold Chain Information Tracing Supplier
China RFID Industry Union Member
3 Beijing Independent Innovation Product Certificates
China Food Cold Chain Information Tracing Supplier
2012 Deloitte Asia Pacific Fast Growing High Tech Enterprise Top 500 Award
2012 Deloitte China Fast Growing High Tech Enterprise Top 50 Award
2012 The National Golden Card Project Gold Ant Award for Product Innovation
2012 China Internet of Things Leading Enterprise
2012 Most Competitive Brands in Pharmaceutical Industry Top 10
13. 中国物联网行业先锋
Top 10 Pharmaceutical Group customers in China
Customer Name Chinese Name Collaboration time
Shanghai Pharma Group 上药集团 08、09、10、11
Kelun Pharmaceutical Group 科伦集团 10、11
Harbin Pharmaceutical Group 哈药集团 08、09、10、11
Guangzhou Pharmaceutical Group 广药集团 09、10、11
China National Biotec Group 中生集团 08、09、10、11
Fosun Pharma Group 复星集团 08、09、10、11
NCPC Pharmaceutical Group 华北制药 08、09、10、11
Sinopharm Group 国药集团 08、09、10、11
Yangtze River Pharmaceutical Group 扬子江药业 08、09、10、11
North China Pharmaceutical Group 东北制药 08、09、10、11
16. 中国物联网行业先锋Background and Status of System
Status
So far four phase drug electronic supervision project had been promoted, and completed the whole
process supervision for six kinds of drugs..
In 2006 Narcotic drugs be the first experimental unit in China
In 2007 Class A psychotropic drugs (18 units in China)
In 2008 Bacterin, blood products, Chinese medicine injections and Class B psychotropic drugs
In 2010 Electronic Drug Monitoring code for the drugs in Essential Drug List
In 2013 Implement Electronic Drug Monitoring Code for imported drugs
In 2015 Complete the code supervision for all drugs. Electronic Drug Monitoring Code
17. 中国物联网行业先锋
CFDA T&T Project
Product File
XML
Electronic
Drug
Monitoring
Code
TXT
Aggregation
XML
Registration and
Sales Verification
Data
XML
Printing/
Stickng
Scanning
barcode
Exception
handle
Aggregation
Stock in
Stock out
Aggregation data file interface
GI/GR Data
interface
RegistrationandSales
VerificationSystem
T&T System
CFDA
Build aggregation
Items/Bundles/Case
18. 中国物联网行业先锋CFDA T&T Project ProcessAfterproduceProduceBeforeproduce
local
CFDA Web site/
Acctrue ESC
Enterprise/
Acctrue
Online approvalCFDA WebsiteEnterprise3、Download the
supervision code
Online applicationCFDA WebsiteEnterprise2,Apply the
supervision code
Online maintenanceCFDA WebsiteEnterprise1、Maintain Product
information
Business flow Operator Platform Place
Printing vendor--------Carton vendor
4、Test on the web
site
Plant officeCFDA WebsiteEnterprise
10、Scan goods
PlantAcctrue ESCEnterprise8、Aggregation
PlantAcctrue ESCEnterprise
7、scan/verify on
the production line
PlantAcctrue ESCEnterprise
6、Bundle/case Barcode
online printing
WarehouseAcctrue ESCEnterprise
CFDA WebsiteEnterprise
11、Upload logistic
data
Flow plan
Plant office
5、Carton vendor
printing
9、Upload batch data
19. 中国物联网行业先锋
Printing Mode of Electronic Drug Monitoring Code
Label
Definition
The label of Electronic Drug Monitoring Code (EDMC)is composed by 20 supervision code
numbers, one barcode and hint information.
The EDMC is the electronic ID number of each independently packaged drug, which can be
divided into the first supervision code, the second supervision code, the third supervision
code, etc.
Label Mode
Mode A
Mode B
Mode C
20. 中国物联网行业先锋大箱监管码赋码规范
Technical Guidance for Drug Electronic Supervision, item3.5. (5) When assigning
supervision codes to the maximum package of the drug, print the same supervision
code label for at least two copies and stick them horizontally on two mutually
orthogonal surfaces of the external package respectively for the convenience of
scanning when piling up the products. It had better to stick the supervision code label
near the product batch number on the external box for the convenience of information
management. In the meantime, to avoid the supervision code getting too close to the
bottom edge so that it becomes unrecognizable, it is recommended to maintain
minimum 30mm from the bottom of the supervision code to the carton bottom edge. As
it is shown in the figure:
21. 中国物联网行业先锋Printing Specification of EDMC Label
Printing technical parameters of EDMC
Code128C
1D Barcode: Code128C
Precision X≥7 mil
Barcode Density: X≥7 mil
H≥ 8mm
Barcode Height: H≥ 8mm
Printing position of EDMC
Facilitate the scanning of production line and build association
relations
Avoid being printed together with product barcode and other barcodes
Printing direction of EDMC
Color matching of EDMC
Printing quality inspection method of EDMC
The grade of barcode reaches C
22. 中国物联网行业先锋
22
The policy of imported drugs
From 2012, some of the import drugs ,for example, narcotics, psychotropic drugs,
blood products, vaccine, Chinese injection drugs as well as the Class B
psychotropic drugs have been brought into the electronic supervision project.
The import drug packaged in China domestic must be stick with barcode label by
the package vendor before 28,Feb, 2013
The import drug packaged in oversea plant, The enterprise must stick the barcode
on the box before 28,Feb,2013, and stick the barcode on each level package
before 31,Dec,2013
The enterprise must ready for the website accession , barcode sticking and
registration
(Extract from the CFDA document[2012] 85, Release at 28,June,2012)
23. 中国物联网行业先锋
23
The latest policy of imported drugs
Both manufacture and package supplier should register a account in china drug admin web site
Import narcotics, psychotropic drugs, blood products, vaccine should be completed after 28,Feb,2013
The muti-level package of these drugs subject to the marked manufacture date, The drugs produced after
Jan 1,2014 must stick the barcode according to the standard
The EDMC code is applied to all levels of sales packaging except for pallets
Aggregation relationships for all levels of packaging must be maintained and included in China government
reporting
The Class B drugs must stick barcode at 12 later when it register in CFDA. All drugs must stick the barcode
at the end of 2015.
The local CFDA supervise the import drugs, the drugs mismatch the standard would be refused.
The supervise organization depends on the registered office.
The photo of EDMC code and lot number must be provided in the process of import drugs check in..
By the deadline of Dec 31 2015, all the import drugs must serialized at the plant that registers on CFDA file,
before entering in China.
http://www.sda.gov.cn/WS01/CL0516/
25. 中国物联网行业先锋What we can offer:
25
1st,Consultation service
1、Policy Interpret,
2、 Technical support ,registration support, test support
3、Business flow planning
4、Risk evaluation, Supplier evaluation
5、Surrounding system integration
2nd,Acctrue ESC software
1、ESC(electronic supervision system)
2、PDM(electronic supervision data management system)
3、Warehouse terminal
3rd,Project implementation
1、Development
2、Software deployment
3、Software deployment/hardware installation debug/production line
improvement
4、Training
5、System validation
4th,Technical support post sale.
1、support for execution flow
2、remote support
3、on site support
26. 中国物联网行业先锋Sample: the consultation delivery
Policy interpret
CFDA Policy summary about electronic supervision
Policy analysis and business influence evaluation
Further explain to supervision specification
CFDA Interface Technical support
Aggregation data interface
Logistic data interface
CFDA software client.
Q&A
Business plan
Survey report to current business flow
General business flow proposal
SOP
Import drugs project proposal
Risk evaluation
Risk evaluation report
Surrounding system integration plan
System interface design document
System interface program
System interface validation
27. 中国物联网行业先锋General Solution
27
Production line
improvement solution
Purchase HW/SW
On site implementation
FAT
IQ,OQ,PQ
SAT
Product information
Local GMP requirement
Survey to production line
IT infrastructure
Surrounding system
34. 中国物联网行业先锋Signal Interface Design(optional)
34
Signal Source Signal Objective NOTES
T&T system Packing Line
If the reject station failed, T&T system client will send
a stop signal to the packing line.
Emergency stop signal: T&T system client will send a
stop signal to packing line.
Packing Line T&T system Emergency stop signal: Packing Line will send a stop
signal to the T&T system client
After the case packer finish a case , it will send a
finished case signal to the T&T system
35. 中国物联网行业先锋Acctrue T&T System (Video)
• Application video on plants
• https://www.youtube.com/watch?v=bSVGKsL2NpU
• https://www.youtube.com/channel/UCuBC0sbQBS7RMQDEeTB78Mw
35
39. 39
中国物联网行业先锋Role/User/ Authority Management
Three grade authority mode
System can grant different permissions to
different role or user, to control whether this role/user
can access the specific function/resource or not
Support to integrate with AD
Strong Password management
Support to lock the production Client
Packing Line permission management
Role Permission
Planning Import product information function
Import EDMC files function
Password management
Export Aggregation file function
Export EDMC file to carton vendor function
Audit trail log (own user actions only – read only)
Operator Hand held scanner functions
Password management
Query EDMC function
Audit trail log (own user actions only – read only)
Packing
line
manager
Production task management function
Production management function
Hand held scanner functions
Query EDMC function
Password management
Audit trail log (own user actions only – read only)
administr
ator
All functions
Audit trail log ( all user actions - read only)
Warehous
e operator
Hand held scanner functions
Password management
Query EDMC function
Export logistics data function
Audit trail log (own user actions only – read only)
QA Hand held scanner functions
Password management
Query EDMC function
Audit trail log (own user actions only – read only)
44. 44
中国物联网行业先锋Early warning
※ It can warning the quantity of the remaining T&T codes
whether is enough. (for pre-print codes)
※ It can notice system administrator by mail.
※When the packing T&T system task be started, system can
check whether the bundle/case codes is enough or not.
45. 中国物联网行业先锋Deployment of Group
Deployment of Group:
Under the deployment of group, the Web server and database server are
severally deployed on the independent physical server. In order to ensure
the performance and high practicability, the Web server and database
server are deployed in the way of Cluster and the coding execution
software is deployed on the single industrial control computer.
Advantages
The database and Web server are separate, which further improves the
processing speed and processing ability of system, provides the ability of
single point fault and increases the reliability and practicability of system.
Scope of application:
Apply to the enterprises with a large number of production lines and great
output, especially to the group enterprises. The production line of the
whole group can be uniformly managed.
45
Plant area 1
Production
line 1 Plant area 2
Machine used for
industrial control 1
Machine used for
industrial control 2
Machine used for
industrial control 3
Machine used for
industrial control 3
Machine used for
industrial control 4
Center computer house
Database server
Web server
Production
line 2 Production
line 3
46. 中国物联网行业先锋
Standard Deployment:
Under the standard mode, the Web server and database server are deployed on a
independent physical server, the coding execution software is installed on the industrial
control computer, the server can manage several industrial control computers, and each
industrial control computer can manage one or several production line.
Pros: Adopting this mode to separate the industrial control computer and server, it can
effectively ensure the pressure of server not too large and the normal production of
industrial control computer.
Cons:A impendent server with UPS is needed and the cost is relatively high;
The database server and Web server are deployed together, which can’t sustain too
many industrial control computers;
Scope of application: apply to the enterprise with many production lines, fast
production speed, great output and normative management.
Standard mode is recommended to the deployment of general enterprise.
46
Standard Deployment (Reference)
47. 中国物联网行业先锋
47
Compact Deployment:
Under the compact mode, the Web server, database server
and coding execution software are synchronously installed on
a same industrial control computer.
Pros:
Three function modules are deployed on an industrial control
computer, which doesn’t need the support of special server
and saves the cost.
Cons:
The industrial control computer has a high load and can’t
complete the production tasks with high speed and large
quantity.
Scope of application:
This mode applies the enterprises with small product package
sorts, small package quantities, slow speed and small package
workshop space or the enterprises with scattered production
line positions.
Compact Deployment (Reference)
48. 中国物联网行业先锋
Advantages of Accture Visual Solution
48
Advance
technology
Mature
interface
Strong
adaptabili
ty to
environme
nt
Advanced technology, visual system could obtain a more
clear image and meet various modes such as character
recognition, bar code recognition and 2-dimentional bar code
recognition, etc.
Having a high tolerance to the
environment and possessing the
industrial level application
technology
Seamless integration with
tagging software
Typical Case of Accture
Visual Solution
Bayer Healthcare (the
first in the
pharmaceuticals industry
in China to adopts visual
solution
Astra Zeneca
Xi’an Janssen
Wuhan Mayinglong
Novartis Pharmacy
49. 中国物联网行业先锋System Abnormality During Production
Power
outage in
production
Self-
restoration
of State
System
crash
Mis-
operation by
the
personnel
Automatic
saving of
production
data
Self-restoration
of production
task
50. 中国物联网行业先锋Providing Customers Training Model
Feel at ease and be bold to operate
Customers
Training Model
Training Produce rubbish data
Influence Production data
Virtual environment
Live experience
Training and learning will be
more visualized and convenient
It will not influence the actual
production environment data
52. 中国物联网行业先锋System Compatibility
52
Database
management
system support
ORACLE or
SQLSERVER
Support multi-version
operation system of Windows
Support all versions of IE
and other mainstream
browsers such as Fire Fox
Support C/S
And B/S Clients
57. 中国物联网行业先锋Post-sales Service
“4 Dimension” Service
1. On-site support
2. 7*24 hot line support
3. Remote support by Acctrue’s senior engineers
4. Train 2 employees into AE ( Engineer up to standards of Acctrue)
Golden Service
Problem clarification time after error reporting, it will be immediately / up 4h
Problem treatment time will be in 1 work day.